Industry
AIDS Activists Obtain Biden-Gilead HIV Prevention Patent Settlement R&D Agreement
AIDS activists have obtained a research and development agreement that formed the basis of a settlement between the Biden administration and Gilead Sciences concerning patents for HIV prevention drugs. The activists are criticizing the terms of the settlement deal. The agreement relates to pre-exposure prophylaxis (PrEP) medications used to prevent HIV transmission. This development follows years of dispute over whether the federal government held patent rights to Gilead's HIV prevention drugs and the terms under which those drugs should be made available.
Why it mattersMedicaid managed care organizations covering HIV prevention services need to monitor how this patent settlement affects PrEP drug pricing, formulary decisions, and access requirements for high-risk populations.